Federal Circuit Endorses the Doctrine of Equivalents Again for Lilly’s ALIMTA®:  Different Amendment, Same Result

December 31, 2020

At 40 Years Old, the Orange Book Gets a Fresh Look as FDA Seeks Comments on Patent Listability

September 18, 2020

Feel Like DOE is Having a Rebirth in Life Science Cases? You’re Not Alone

July 11, 2020

Even If the Federal Circuit Could Award Attorney Fees for IPR Appeals, § 285 Does Not Permit It to Award Fees Incurred During the IPR

June 11, 2020

Update: Recent International Activity on IP in Response to COVID-19

May 26, 2020

New Treatments for COVID-19: Recent International Activity Relating to IP and Some Tools the US Already Has in Place

April 9, 2020

“Numerous Reasons” Support Finding Inequitable Conduct: Another Example of the Federal Circuit’s Current Approach to Inequitable Conduct

April 2, 2020

Delaware Provides More Insight into the Scope of the Rights Derived by a Patent Term Extension

February 21, 2020